Boundless Bio's Upcoming Conference Participation
Boundless Bio, a groundbreaking clinical-stage oncology company, has announced its participation in an important healthcare conference. Zachary Hornby, the President and Chief Executive Officer of Boundless Bio, will be engaging in a fireside chat during the event, where he is expected to share valuable insights about the company’s innovative approaches in cancer treatment.
Details of the Conference Event
The fireside chat session is set to take place on a Wednesday morning in December. Attendees and investors can look forward to the live event, and a recorded version will be made available on Boundless Bio’s website under the "Events & Presentations" section. This access will enable interested parties to revisit the discussion and gather further insights into the future directions of the company.
About Boundless Bio
Boundless Bio is committed to revolutionizing cancer therapeutics through its focus on extrachromosomal DNA (ecDNA), which is linked to oncogene amplification in a notable percentage of cancer cases. This not only emphasizes the importance of their work but also highlights the particular unmet need that the company strives to address. Their mission revolves around transforming cancer treatments particularly for patients who face significant challenges with existing therapies.
Innovative Therapeutic Candidates
The company is advancing its pioneering therapeutic candidates: BBI-355, which targets checkpoint kinase 1 (CHK1), and BBI-825, an inhibitor of ribonucleotide reductase (RNR). These investigational drugs are being studied in conjunction with other therapies in the ongoing phase 1/2 POTENTIATE clinical trial, aiming to maximize their efficacy in individuals battling oncogene amplified cancers.
Advancements in Research and Development
Additionally, Boundless Bio is in the process of conducting IND-enabling studies for another innovative ecDNAdirected therapeutic, known as BBI-940. This is poised to potentially be a first-in-class orally bioavailable Kinesin degrader, targeting cancer at a foundational level. The company is based in San Diego and is leading the charge in developing strategies aimed at significantly improving patient outcomes.
Connecting with Boundless Bio
For those interested in the continued developments within Boundless Bio, further information can be found directly on their official website. The company also maintains a presence on multiple social media platforms allowing stakeholders to stay updated on their latest advancements and news. Engaging with the company’s content will provide opportunities to learn more about their innovative solutions in oncology.
Frequently Asked Questions
What is the main focus of Boundless Bio?
Boundless Bio focuses on developing cancer therapies targeting extrachromosomal DNA to treat oncogene amplified cancers.
When and where is the conference session taking place?
The conference session is scheduled for a Wednesday morning in December.
What therapeutic candidates is Boundless Bio developing?
Boundless Bio is developing BBI-355 and BBI-825 as therapeutic candidates for cancer treatment.
Where can I find more information about Boundless Bio?
More information can be accessed on Boundless Bio's official website and their social media platforms.
Who is the CEO of Boundless Bio?
Zachary Hornby is the President and CEO of Boundless Bio.